DK2350268T3 - Fremgangsmåde til produktion af adenovirusvektorer - Google Patents

Fremgangsmåde til produktion af adenovirusvektorer Download PDF

Info

Publication number
DK2350268T3
DK2350268T3 DK09744140.6T DK09744140T DK2350268T3 DK 2350268 T3 DK2350268 T3 DK 2350268T3 DK 09744140 T DK09744140 T DK 09744140T DK 2350268 T3 DK2350268 T3 DK 2350268T3
Authority
DK
Denmark
Prior art keywords
cells
cell
rad35
bioreactor
adenovirus
Prior art date
Application number
DK09744140.6T
Other languages
English (en)
Inventor
Alfred Luitjens
John Alfred Lewis
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of DK2350268T3 publication Critical patent/DK2350268T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M3/00—Tissue, human, animal or plant cell, or virus culture apparatus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Sustainable Development (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Claims (7)

1. Fremgangsmåde til produktion af rekombinant adenovirus serotype 35 (rAd35) i en bioreaktor, hvilken fremgangsmåde omfatter: a) dyrkning af PER.C6-celler i suspension i en bioreaktor med et perfusionssystem; b) inficering af cellerne i en bioreaktor ved en densitet på mellem 10 x 106 levedygtige celler/ml og 16 x 106 levedygtige celler/ml med rAd35; c) yderligere dyrkning af de inficerede celler i en bioreaktor med et perfusionssystem til opformering af rAd35; og d) høst af rAd35.
2. Fremgangsmåde ifølge krav 1, hvor cellerne in trin b) inficeres med rAd35 ved en densitet på mellem ca. 10 x 106 og 14 x 106 levedygtige celler/ml.
3. Fremgangsmåde ifølge et hvilket som helst af ovennævnte krav, hvor perfusionssystemet i trin c) er et perfusionssystem med alternerende tangentialt flow (ATF).
4. Fremgangsmåde ifølge et hvilket som helst af ovennævnte krav, der yderligere omfatter: e) oprensning af rAd35 og eventuelt f) fremstilling af et farmaceutisk præparat, der indeholder det oprensede rAd35.
5. Fremgangsmåde ifølge et hvilket som helst af ovennævnte krav, hvor det rekombinante adenovirus mangler mindst en del af El-området og omfatter heterolog nukleinsyre.
6. Fremgangsmåde ifølge et hvilket som helst af ovennævnte krav, hvor perfusionssystemet i trin a) er et perfusionssystem med alternerende tangentialt flow (ATF).
7. Fremgangsmåde ifølge et hvilket som helst af ovennævnte krav, hvor trin a) udføres i en første bioreaktor, og trin b) og c) udføres i en anden bioreaktor.
DK09744140.6T 2008-11-03 2009-10-29 Fremgangsmåde til produktion af adenovirusvektorer DK2350268T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19812208P 2008-11-03 2008-11-03
EP08168181 2008-11-03
PCT/EP2009/064265 WO2010060719A1 (en) 2008-11-03 2009-10-29 Method for the production of adenoviral vectors

Publications (1)

Publication Number Publication Date
DK2350268T3 true DK2350268T3 (da) 2015-03-23

Family

ID=40344776

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09744140.6T DK2350268T3 (da) 2008-11-03 2009-10-29 Fremgangsmåde til produktion af adenovirusvektorer

Country Status (16)

Country Link
US (1) US10041049B2 (da)
EP (1) EP2350268B1 (da)
JP (1) JP5770633B2 (da)
KR (1) KR101504392B1 (da)
CN (1) CN102203242B (da)
AU (1) AU2009319254B2 (da)
BR (1) BRPI0921651A2 (da)
CA (1) CA2742474C (da)
DK (1) DK2350268T3 (da)
EA (1) EA019928B1 (da)
ES (1) ES2532015T3 (da)
HK (1) HK1160664A1 (da)
MX (1) MX2011004292A (da)
NZ (1) NZ593235A (da)
PL (1) PL2350268T3 (da)
WO (1) WO2010060719A1 (da)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA019928B1 (ru) 2008-11-03 2014-07-30 Круселл Холланд Б.В. Способ получения аденовирусных векторов
ES2445713T3 (es) 2009-10-15 2014-03-04 Crucell Holland B.V. Proceso para la purificación de adenovirus a partir de cultivos de alta densidad celular
ES2472429T3 (es) 2009-10-15 2014-07-01 Crucell Holland B.V. Método para la purificación de partículas de adenovirus a partir de cultivos de alta densidad celular
BR112012019023B1 (pt) * 2010-02-15 2021-12-21 Janssen Vaccines & Prevention B.V. Método para produzir adenovírus recombinante sorotipo 26 (rad26), e, uso de um biorreator
AP3390A (en) 2010-09-20 2015-08-31 Crucell Holland Bv Therapeutic vaccination against active tuberculosis
CA2809463C (en) 2010-09-27 2021-05-25 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
EP2673072B1 (en) 2011-02-10 2014-11-19 Crucell Holland B.V. Pneumatic alternating pressure membrane cell separation system
EP2780034A1 (en) 2011-11-14 2014-09-24 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
CA2864956C (en) 2012-03-12 2021-11-09 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
AU2013237429B2 (en) 2012-03-22 2015-07-23 Crucell Holland B.V. Vaccine against RSV
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
EA035522B1 (ru) 2013-04-25 2020-06-29 Янссен Вэксинс Энд Превеншн Б.В. Стабильные растворимые f-полипептиды rsv в конформации "до слияния"
CA2914792C (en) 2013-06-17 2024-02-27 Crucell Holland B.V. Stabilized soluble pre-fusion rsv f polypeptides
BE1022132B1 (fr) * 2013-08-30 2016-02-19 Glaxosmithkline Biologicals S.A. Nouvelle methode.
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
SG11201702997YA (en) 2014-11-04 2017-05-30 Janssen Vaccines & Prevention Bv Therapeutic hpv16 vaccines
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
IL288541B (en) 2015-07-07 2022-08-01 Janssen Vaccines Prevention B V vaccine against rsv
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
US9663766B2 (en) 2015-07-24 2017-05-30 Bio-Rad Laboratories, Inc. Methods for purifying adenovirus vectors
MX2018002106A (es) 2015-08-20 2018-06-15 Janssen Vaccines & Prevention Bv Vacunas terapeuticas contra el hpv18.
JP7233928B2 (ja) 2016-04-05 2023-03-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｒｓｖに対するワクチン
SG11201807913XA (en) 2016-04-05 2018-10-30 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f proteins
EP3442688A4 (en) * 2016-04-12 2019-11-20 Artemis Biosystems, Inc. FILTRATION SYSTEMS FOR INFUSION
CA3021341A1 (en) 2016-05-02 2017-11-09 Janssen Vaccine & Prevention B.V. Therapeutic hpv vaccine combinations
CN109415696A (zh) 2016-05-25 2019-03-01 泰尔茂比司特公司 细胞扩增
IL264119B2 (en) 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
JP7229151B2 (ja) 2016-07-14 2023-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｈｐｖワクチン
EP3601521A2 (en) 2017-03-31 2020-02-05 Terumo BCT, Inc. Cell expansion
AU2018267971A1 (en) 2017-05-17 2019-11-07 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
US11229695B2 (en) 2017-09-15 2022-01-25 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV
MA50502A (fr) 2017-10-31 2020-09-09 Janssen Vaccines & Prevention Bv Adénovirus et utilisations associées
BR112020007698A2 (pt) 2017-10-31 2020-10-06 Janssen Vaccines & Prevention B.V. Sequência de ácido nucleico isolada, vetor, seu método de produção, célularecombinante, composição imunogênica, método para induzir uma resposta imune em um indivíduo, vacina e seu método de produção
EA202091039A1 (ru) 2017-10-31 2020-08-10 Янссен Вэксинс Энд Превеншн Б.В. Аденовирусные векторы и пути их применения
EA202091074A1 (ru) 2017-10-31 2020-07-22 Янссен Вэксинс Энд Превеншн Б.В. Аденовирус и его применения
BR112020011627A2 (pt) * 2017-12-11 2020-11-17 Amgen Inc. processo de fabricação contínuo para produtos de anticorpos biespecíficos
CN110317832B (zh) * 2018-03-28 2022-07-05 西比曼生物科技（香港）有限公司 Gmp级规模化制备重组慢病毒载体的纯化制剂的方法
CN110317791A (zh) 2018-03-29 2019-10-11 西比曼生物科技（香港）有限公司 Gmp级无血清悬浮细胞大规模生产慢病毒的方法
US20210047626A1 (en) 2018-04-24 2021-02-18 Merck Sharp & Dohme Corp. Scalable chromatography process for purification of human cytomegalovirus
MX2022000002A (es) * 2019-07-01 2022-03-17 Ology Bioservices Inc Método para cultivo de células adherentes en un biorreactor multiparalelo.
US11498944B2 (en) 2020-01-31 2022-11-15 Janssen Pharmaceuticals, Inc. Compositions and methods for preventing and treating coronavirus infection—SARS-CoV-2 vaccines
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
EP4225382A2 (en) 2020-10-07 2023-08-16 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21
MX2023011629A (es) 2021-04-01 2023-10-13 Janssen Vaccines & Prevention Bv Proteinas piv3 f prefusion estabilizadas.
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023110618A1 (en) 2021-12-16 2023-06-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2024061753A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized trimeric class i fusion proteins
WO2024061757A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Pre-fusion human piv1 f proteins
WO2024074584A1 (en) 2022-10-06 2024-04-11 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion piv3 f proteins

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04241381A (ja) * 1991-01-16 1992-08-28 Brother Ind Ltd 電子学習機
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
EP1548118A2 (en) * 1994-06-10 2005-06-29 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5851806A (en) * 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5965541A (en) * 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
ES2333425T5 (es) * 1995-06-15 2012-08-28 Crucell Holland B.V. Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica
JPH11511326A (ja) 1995-08-30 1999-10-05 ジエンザイム コーポレイション アデノウィルスおよびａａｖの精製
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
CA2177085C (en) * 1996-04-26 2007-08-14 National Research Council Of Canada Adenovirus e1-complementing cell lines
AU3447097A (en) * 1996-07-01 1998-01-21 Rhone-Poulenc Rorer S.A. Method for producing recombinant adenovirus
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
ATE348155T1 (de) 1996-11-20 2007-01-15 Introgen Therapeutics Inc Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
CA2283253A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US6020191A (en) * 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
SK11842000A3 (sk) 1998-02-17 2001-05-10 Schering Corporation Prostriedok obsahujúci vírus, spôsob jeho koncentrácie a purifikácie
US5981225A (en) * 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
PL343630A1 (en) * 1998-04-22 2001-08-27 Genvec Inc Efficient purification of adenovirus
US6113913A (en) * 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US20040043489A1 (en) * 1998-07-08 2004-03-04 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
ES2323991T3 (es) 1998-11-16 2009-07-28 Introgen Therapeutics, Inc. Formulacion de adenovirus para terapia genica.
PL349074A1 (en) * 1998-12-31 2002-07-01 Aventis Pharma Sa Method for separating viral particles
DE60029195T2 (de) 1999-02-22 2007-06-28 Transgene S.A. Verfahren zur Gewinnung von purifizierter Virenzusammensetzung
PT1816204E (pt) 1999-05-17 2011-01-24 Crucell Holland Bv Adenovírus recombinante do serótipo ad26
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) * 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US6544424B1 (en) * 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
EP1263461A4 (en) 2000-03-07 2009-08-12 Merck & Co Inc ADENOVIRUS FORMULATIONS
DE60138403D1 (de) * 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
EP1453537A1 (en) 2001-12-12 2004-09-08 FH Faulding & Co. Limited Composition for viral preservation
US20040002060A1 (en) * 2002-01-24 2004-01-01 Novartis Ag Fiber shaft modifications for efficient targeting
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
BR0308783A (pt) 2002-04-25 2005-01-04 Crucell Holland Bv Vetor de adenovìrus recombinante, método para produzir um vetor de adenovìrus recombinante, composição farmacêutica, método para tratar um corpo humano, e, kit de partes
WO2004001032A2 (en) * 2002-04-25 2003-12-31 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
DE60335672D1 (de) * 2002-05-14 2011-02-17 Merck Sharp & Dohme Verfahren zur reinigung von adenovirus
US20080153083A1 (en) * 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
WO2004037294A2 (en) * 2002-10-23 2004-05-06 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
NZ539813A (en) * 2002-12-17 2008-04-30 Crucell Holland Bv A replication defective recombinant adenovirus comprising a antigenic determinant of Plasmodium falciparum wherein the antigenic determinant is SEQ ID 6
WO2004099422A2 (en) * 2003-03-28 2004-11-18 The Scripps Research Institute Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
KR101203817B1 (ko) * 2003-10-02 2012-11-23 크루셀 홀란드 비.브이. 재조합 아데노바이러스를 위한 포장 세포
NZ548495A (en) * 2004-02-23 2009-05-31 Crucell Holland Bv Virus purification methods
CN104593277A (zh) * 2004-03-05 2015-05-06 帝斯曼知识产权资产管理有限公司 用于通过连续灌注和交互切向流来培养细胞的方法
MXPA06014099A (es) 2004-06-04 2007-05-09 Xcellerex Inc Sistemas biorreactores desechables y metodos.
US7741099B2 (en) * 2004-10-13 2010-06-22 Beth Israel Deaconess Medical Center Inc. Adenoviral vectors and uses thereof
JP5108521B2 (ja) * 2004-10-14 2012-12-26 クルセル ホランド ベー ヴェー マラリア初回免疫／追加免疫ワクチン
AU2005305869B2 (en) 2004-11-16 2010-12-09 Aeras Global Tb Vaccine Foundation Multivalent vaccines comprising recombinant viral vectors
JP2008538894A (ja) 2005-02-11 2008-11-13 メルク エンド カムパニー インコーポレーテッド アデノウイルス血清型２６ベクター、核酸およびそれにより製造されたウイルス
ATE412737T1 (de) * 2005-04-11 2008-11-15 Crucell Holland Bv Virusreinigung mit ultrafiltration
EP1899470A4 (en) * 2005-05-23 2009-07-29 Vaxin Inc SYSTEM FOR THE FAST MANUFACTURE OF REPLICATED COMPETENCE OF ADENOVIRUS-FREE RECOMBINANT ADENOVIRUS VECTORS WITH HIGH TITER
WO2007010409A2 (en) 2005-07-22 2007-01-25 Pergo (Europe) Ab Flooring system including a preglue
JP2009512421A (ja) * 2005-08-15 2009-03-26 ヴァクシン インコーポレイテッド 非複製性ベクターワクチン投与による鳥類への免疫方法
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
WO2007110409A1 (en) 2006-03-27 2007-10-04 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
EP2040743B1 (en) * 2006-07-18 2013-10-02 GlaxoSmithKline Biologicals S.A. Vaccines for malaria
PL2137210T3 (pl) * 2007-03-02 2017-06-30 Glaxosmithkline Biologicals Sa Nowy sposób i kompozycje
US9109193B2 (en) 2007-07-30 2015-08-18 Ge Healthcare Bio-Sciences Corp. Continuous perfusion bioreactor system
CN101855371A (zh) 2007-11-14 2010-10-06 张惇杰 制备用于锂离子电池应用的空气敏感性电极材料的方法和装置
WO2009117134A2 (en) * 2008-03-21 2009-09-24 National Institutes Of Health Aerosolized genetic vaccines and methods of use
EA019928B1 (ru) 2008-11-03 2014-07-30 Круселл Холланд Б.В. Способ получения аденовирусных векторов
WO2011006823A1 (en) 2009-07-16 2011-01-20 Crucell Holland B.V. Production of polio virus at high titers for vaccine production
ES2445713T3 (es) 2009-10-15 2014-03-04 Crucell Holland B.V. Proceso para la purificación de adenovirus a partir de cultivos de alta densidad celular
US20120315696A1 (en) 2010-02-15 2012-12-13 Alfred Luitjens METHOD FOR THE PRODUCTION OF Ad26 ADENOVIRAL VECTORS
BR112012019023B1 (pt) 2010-02-15 2021-12-21 Janssen Vaccines & Prevention B.V. Método para produzir adenovírus recombinante sorotipo 26 (rad26), e, uso de um biorreator

Also Published As

Publication number Publication date
CA2742474A1 (en) 2010-06-03
EA019928B1 (ru) 2014-07-30
EP2350268B1 (en) 2014-12-24
US20110207202A1 (en) 2011-08-25
MX2011004292A (es) 2011-05-31
AU2009319254B2 (en) 2015-04-30
EA201170638A1 (ru) 2011-12-30
CN102203242A (zh) 2011-09-28
NZ593235A (en) 2013-02-22
AU2009319254A1 (en) 2010-06-03
PL2350268T3 (pl) 2015-05-29
CA2742474C (en) 2016-05-31
EP2350268A1 (en) 2011-08-03
JP2012507270A (ja) 2012-03-29
US10041049B2 (en) 2018-08-07
CN102203242B (zh) 2013-06-12
WO2010060719A1 (en) 2010-06-03
HK1160664A1 (en) 2012-08-10
JP5770633B2 (ja) 2015-08-26
KR20110093793A (ko) 2011-08-18
BRPI0921651A2 (pt) 2015-08-18
KR101504392B1 (ko) 2015-03-19
ES2532015T3 (es) 2015-03-23

Similar Documents

Publication Publication Date Title
DK2350268T3 (da) Fremgangsmåde til produktion af adenovirusvektorer
CA2786835C (en) Method for the production of ad26 adenoviral vectors
US20180080010A1 (en) Method for the production of ad26 adenoviral vectors
US8574595B2 (en) Virus purification using ultrafiltration
US8124106B2 (en) Virus purification methods
WO2022123033A1 (en) Method for producing virus